Feature | EP Lab | May 09, 2016

Lead Removal Has High Success Rate in International Study

First prospective, multinational study on rapidly growing procedure presented at Heart Rhythm 2016

May 9, 2016 – A new, large study shows that 95.7 percent of individual leads were successfully removed using a procedure called transvenous lead extraction (TLE). The ELECTRa (European Lead Extraction ContTRolled) Registry, hosted by the European Heart Rhythm Association (EHRA) a registered branch of the European Society of Cardiology (ESC), is the first multinational, multi-center, prospective registry of consecutive patients undergoing TLE. 

The research was presented at Heart Rhythm 2016, the Heart Rhythm Society’s annual scientific meeting, and includes data from both high volume and low volume medical centers.

The rate of cardiac rhythm device implantation such as pacemakers or defibrillators is on the rise and therefore complications are increasing, leading to a parallel growth of the TLE procedure. There are occasions when it is necessary to remove a device and any associated leads when there is infection, venous occlusion, lead malfunction or failure, or safety alerts. While TLE has become a central treatment option for patients, the safety and efficacy can vary widely.

Data from 73 centers across 19 countries of the ESC were collected using a web-based system.

The primary objective was to evaluate the acute and long-term safety of TLE. The secondary objective included the description of patient characteristics, types of leads, indications for TLE, extraction techniques, success rates of TLE and the comparison between low and high volume centers. A high volume center is considered one that sees an average of 30 patients a year (or 2.5 patients a month) and a low volume center sees less than 30 patients per year.

A total of 3,555 consecutive patients undergoing extraction of 6,493 leads were enrolled in the registry. Leads were extracted from the right atrium, right ventricle, coronary sinus and other locations. Major and minor complications were 2.7 percent and 5.2 percent, respectively. High volume centers had fewer major (2.4 percent vs. 4.1 percent) and minor (4.5 percent vs. 8.1 percent) complications compared to low volume centers. Procedure-related major complications occurred in 58 patients (1.7 percent). The most common procedure related complications were cardiovascular complications requiring surgical repair, pericardiocentesis or chest drain insertion.

“The success rates of our study were higher than originally predicted, which is encouraging. This is the first time that we’re seeing the safety of transvenous lead extraction in a large group of patients on a prospective, consecutive basis, which is clinically important. We can now use these results to further testify that TLE is an effective option to improve the quality of care for patients undergoing lead extraction,” said Maria Grazia Bongiorni, M.D., University Hospital of Pisa in Italy. “While we saw great success rates, device therapy still poses many risks and complications, so it’s important that we continue to explore and push the boundaries for new technologies like embracing leadless pacemakers as the way of the future.”

The authors also looked at 12-month follow-up data and observed 3.2 percent of complications related to infection and 5.2 percent of complications related to non-infection conditions.

For more information: www.HRSonline.org

Related Content

Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

News | Cardiovascular Clinical Studies | July 22, 2020
July 22, 2020 — Eating chocolate at least once a week is linked with a reduced risk of heart disease, according to re
The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp